Epilepsy, Complex Partial Clinical Trial
Official title:
A Double-Blind, Randomized, Multicenter, Parallel Group Study to Establish Dose-Response, Safety, and Efficacy of Zonegran (Zonisamide) as Monotherapy in Patients With Newly Diagnosed Epilepsy
The purpose of this study is to determine whether zonisamide alone is effective as a treatment for epilepsy in newly diagnosed cases.
Epilepsy is characterized by repeated seizures caused by recurrent, abnormal, and excessive synchronous discharges from cerebral neurons. Seizures may be triggered by various causes such as CNS infections, fever, tumors, toxins, vascular disease, degenerative disease, trauma, or may be idiopathic. The type of seizure is usually defined by the initial event, the duration, alterations of consciousness, patterns of motor activity, and post-ictal symptoms. In addition, certain seizure types have characteristic EEG patterns. The International Classification of Epileptic Seizures classifies seizures as partial or generalized. Partial seizures are further classified as simple partial, complex partial (impaired consciousness), or partial seizures secondarily generalized. All partial seizures have onset in a discrete cortical region. Generalized seizures are bilaterally symmetrical and without focal onset and include absence seizures, myoclonic seizures, clonic seizures, tonic seizures, tonic-clonic seizures, and atonic seizures. The goals of treatment include the prevention of seizures, medical management of seizures, and management of the consequences of epilepsy. The study will be conducted with patients who have new onset epilepsy characterized by complex partial seizures and will attempt to characterize the relationship between zonisamide dose and seizure prevention and demonstrate monotherapy efficacy. ;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00143143 -
Pregabalin Open-Label Extension Trial in Patients With Partial Seizures
|
Phase 3 | |
| Completed |
NCT01002820 -
A Treatment Use Protocol for Subjects Continuing on From the Open-label Extension 0601
|
Phase 2 | |
| Completed |
NCT00001489 -
Effect of Vigabatrin on Brain Blood Flow and Glucose Metabolism
|
N/A | |
| Completed |
NCT00433667 -
A Study of the Efficacy and Safety of RWJ-333369 as add-on Therapy in the Treatment of Partial Onset Seizures.
|
Phase 3 | |
| Completed |
NCT00425282 -
A Study of the Efficacy and Safety of RWJ-333369 as add-on Therapy in the Treatment of Partial Onset Seizures.
|
Phase 3 | |
| Completed |
NCT03156439 -
Bioavailability, Safety, and Tolerability of BIS-001 ER
|
Phase 1 | |
| Completed |
NCT04573569 -
Neural Correlates of Cognition and Mood
|
||
| Completed |
NCT00744731 -
An Open-Label Extension Study of the Safety and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures
|
Phase 3 | |
| Completed |
NCT00740623 -
A Study of the Effectiveness, Safety, and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures.
|
Phase 3 | |
| Completed |
NCT00319501 -
Efficacy and Safety of Vanquix for the Management of Selected, Refractory, Patients With Epilepsy Who Require Intermittent Caregiver Medical Intervention to Control Episodes of Acute Repetitive Seizures.
|
Phase 3 | |
| Completed |
NCT00991757 -
An Open-Label Extension Study to Evaluate the Safety and Tolerability of RWJ 333369 as Adjunctive Therapy in Patients 16 Years and Older With Partial Onset Seizures.
|
Phase 3 | |
| Terminated |
NCT01128712 -
Effect on Anxiety in Partial Epilepsy Patients Treated With Pregabalin
|
Phase 4 |